GameStop Corp. vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? GameStop Corp. trades at $26.56 (market cap $12.75B), while Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B). The key difference: GameStop Corp. is far larger — about 2.1× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is more actively traded (14,805,993 versus 13,026,993). Which is the better fit depends on your goals — on Pluang, investors hold GameStop Corp. for 62 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| GME | IOVA | |
|---|---|---|
Market Cap | $12.75B | $6.04B |
Volume | 13,026,993 | 14,805,993 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.53 | $14.82 |
52-Week Low | $17.87 | $1.81 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $12.03B | $5.97B |
Signals from Pluang's Aura AI — not financial advice
GME trades at $25.28, up 2.85% today, with a bullish technical signal and strong insider buying. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. The company's balance sheet is robust with $4.77 billion in cash and low debt, while profitability improved significantly with a net income margin of 3.43% in 2025.
Outlook remains positive due to strong cash reserves and insider confidence, but risks include revenue decline and competitive pressures. Analyst consensus is cautious with only 16.67% buy ratings. The stock's valuation metrics suggest moderate pricing relative to earnings and sales.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →